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The ability to predict complete pathologic response or sensitivity to radiation before treatment would have a significant impact on the
selection of patients for preoperative radiotherapy or chemo-radiation therapy schedules. The aim of this study was to determine the
value of epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), p53, Bcl-2 and apoptosis protease-
activating factor-1 (APAF-1) as predictors of complete pathologic tumour regression in patients undergoing preoperative
radiotherapy for advanced rectal cancer. Pretreatment tumour biopsies from predominantly cT3 patients undergoing a preoperative
high-dose-rate brachytherapy protocol were immunostained for EGFR, VEGF, p53, Bcl-2 and APAF-1. Immunoreactivity was
evaluated by three pathologists. Cut-off scores for tumour marker positivity were obtained by receiver-operating characteristic
(ROC) curve analysis. The association of marker expression with complete pathologic response was analysed in univariate and
multivariable analysis. Multi-marker phenotypes of the independent protein markers were evaluated. In multivariable analysis, loss of
VEGF (P-value¼0.009; odds ratio (OR) (95% CI)¼0.24 (0.08–0.69)) and positive EGFR (P-value¼0.01; OR (95% CI)¼3.82
(1.37–10.6)) both demonstrated independent predictive value for complete pathologic response. The odds of complete response
were 12.8 for the multi-marker combination of VEGF-negative and EGFR-positive tumours. Of the 34 EGFR-negative- and VEGF-
positive cases, 32 (94.1%) had no complete pathologic response. The combined analysis of VEGF and EGFR is predictive of complete
pathologic response in patients undergoing preoperative radiotherapy. In addition, the findings of this study have identified a subgroup
of simultaneous EGFR-negative and VEGF-positive patients who are highly resistant to radiotherapy and should perhaps be
considered candidates for innovative neoadjuvant combined modalities.
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Colorectal cancer is a leading cause of cancer-related mortality and
morbidity in the Western world, with 5-year survival rates ranging
from 90 to 10% with tumour progression (O’Connell et al, 2004).
Patients with rectal cancers, comprising approximately 30% of
these cases, are known to have an increased rate of local recurrence
and decreased survival time compared with patients with tumours
of the colon, a result due primarily to the surgical constraints
imposed by the location of the rectum within the pelvis (Wolpin
et al, 2007). As a consequence, the clinical management of patients
with rectal cancer differs significantly from that of the colon in
terms of surgical technique, the more frequent use of radiotherapy
and method of chemotherapy administration.
Evidence from randomised clinical trials, meta-analyses and
epidemiologic studies strongly support the treatment of rectal
cancer with preoperative modalities (Colorectal Cancer Collaborative
Group, 2001; Wong et al, 2007). The Swedish Rectal Cancer
Trial was the first to demonstrate an independent survival benefit
and significant improvement in local control with preoperative
short-course radiotherapy (25Gy delivered in five fractions over 1
week) compared with surgery alone (Swedish Rectal Cancer
Trial Group, 1997). Similar findings were derived from the
Stockholm II Trial with the same fractionation regimen (Martling
et al, 2001). Recently, short-course preoperative radiotherapy
was found to decrease these rates even further in combination
with total mesorectal excision (TME) (Kapiteijn et al, 2001).
Short-course continuous, hyperfractionated, accelerated radiation
therapy (CHART) and conformal high-dose-rate endorectal
brachytherapy (HDREB) have demonstrated high rates of complete
pathologic response as well as acceptable toxicity levels
and tolerable side effects (Vuong et al, 2002, 2007; Brooks et al,
2006).
Several pathological features have been identified as prognostic
factors in patients undergoing preoperative radiotherapy with or
without chemotherapy. The circumferential resection margin
status significantly affects prognosis with 5-year overall- and
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srecurrence-free survival, decreasing substantially with increasing
R-stage (den Dulk et al, 2007; Eriksen et al, 2007; Larsen et al,
2007). Ro ¨del and co-workers investigated the tumour regression
grade (TRG) on 5-year disease-free survival in more than 350
patients (Rodel et al, 2005). An independent adverse prognostic
effect was observed in patients with low TRG. Kuo et al (2007)
noted an improved survival in patients with complete pathologic
response and a decreased prognosis in patients with more
advanced post-treatment TNM stage. Das et al (2007) observed
an association between complete pathologic response and loco-
regional control.
In addition to these pathological prognostic factors, which can
only be identified post-surgically, molecular characterisation is
expected to improve the identification of more aggressive or
treatment-resistant tumours before therapy. Recently, microarray
gene expression profiling was successfully used to predict
complete responses to preoperative chemoradiotherapy with
advanced-stage rectal cancer (Ghadimi et al, 2005; Kim et al,
2007). Epidermal growth factor receptor (EGFR), vascular
endothelial growth factor (VEGF), the p53 tumour suppressor
and key mediators of cell-cycle arrest (p21, p27) and apoptosis
(Bcl-2, apoptosis protease-activating factor-1 (APAF-1)) are
among the immunohistochemical protein markers currently of
interest as potential predictors of pathologic response, prognosis
and recurrence-free survival in rectal cancer following neoadjuvant
therapy (Giralt et al, 2005, 2007; Lopez-Crapez et al, 2005; Kim
et al, 2006; Lin et al, 2006; Smith et al, 2006; Bertolini et al, 2007).
The aim of this study was to predict complete pathological
tumour regression to preoperative HDREB by investigating the
combined immunohistochemical expression of EGFR, VEGF, p53,
Bcl-2 and APAF-1 in 104 pretreatment biopsies from patients with
advanced rectal cancer.
MATERIALS AND METHODS
Preoperative HDREB
This study was approved by the Research Ethics Committee
of the McGill University Health Center. One hundred and four
patients with newly diagnosed invasive, resectable rectal adeno-
carcinoma were included in this study and informed written
consent was obtained. Preoperative staging was performed
according to the International Union against Cancer Classification
and carried out by endorectal ultrasonography and magnetic
resonance imaging (MRI). Eligible patients included those with
large T2 tumours located in the middle 1/3 of the rectum, T3 and
early T4 tumours. Patients with abdominal nodal disease,
metastases and small T2 tumours with favourable features were
excluded from the study. Tumour sizes ranged from 3 to 5cm in
diameter. Radiation was delivered preoperatively with a multi-
channel endorectal applicator (Novi Sad and recently with the
Oncosmart Nucleotron B.V., Veenendaal, Netherlands) and a high-
dose-rate remote after-loading system using an Iridium-192 source
(Vuong et al, 2007). A daily fraction of 6.5Gy was administered
over four consecutive days up to a total of 26Gy. Each patient was
planned with endorectal applicator in place using a CT simulator
(Pickler International Inc., Highland Heights, OH, USA) in order
to obtain optimal conformal dosimetry. The dose was prescribed
to a clinical target volume that included the gross tumour volume
and any intramesorectal deposits visible at MRI. Patients under-
went surgery 4–8 weeks after brachytherapy as planned before
treatment regardless of tumour response.
The assessment of tumour response was performed by pathologic
evaluation of rectal specimens postoperatively. Tumours considered
to be completely responsive to preoperative HDREB had no
histologic evidence of residual viable carcinoma (ypT0). Tumours
with microfoci, foci or large areas of residual carcinoma were
considered partially or non-responsive to treatment.
Immunohistochemistry
Immunohistochemistry for EGFR, VEGF, p53, Bcl-2 and APAF-1
was carried out on formalin-fixed, paraffin-embedded serial
sections cut at 3mm and dried at 371C overnight. Immunostaining
was performed using the avidin–biotin complex (ABC) procedure,
including heat-induced epitope retrieval and enzymatic antigen
retrieval procedures. Incubation was carried out overnight at 41C
for Bcl-2 (clone 124; DAKO, Glostrup, Denmark, 1:100) and VEGF
(VEGF-A20; Santa Cruz Biotechnology, Santa Cruz, CA, USA,
1:100), and in a moist chamber at 371C for 1h for p53 (clone
DO-7; DAKO, Denmark, 1:100) and APAF-1 (NCL-APAF-1;
Novocastra, Newcastle, UK, 1:100). Immunohistochemistry for
EGFR (clone 3C6, 3mgml
 1; Ventana Medical Systems, Tucson,
AZ, USA) was performed using an autostainer according to
manufacturer’s instructions. Negative controls were treated
identically, with primary antibodies omitted.
Evaluation of immunohistochemistry
Immunoreactivity was evaluated in a semi-quantitative manner
from pretreatment biopsy specimens. The proportion of immuno-
reactive tumour cells over the total number of tumour cells by 5%
increments (0, 5, 10, and so on up to 100%) was determined
by three pathologists (A Lugli, JR Jass, S Hayashi) for EGFR and by
four pathologists (CC Compton, A Lugli, JR Jass, RP Michel) for
p53, Bcl-2, VEGF and APAF-1. This scoring method was previously
found to be highly reproducible between pathologists (Zlobec et al,
2006a, 2007c). Only areas of invasive carcinoma were analysed.
Protein expression was not evaluated in biopsies lacking sufficient
tissue for immunohistochemical evaluation. Staining was assessed
in the nucleus for p53 and in the cytoplasm for VEGF, Bcl-2 and
APAF-1. Immunoreactivity for EGFR expression was assessed in
both cytoplasm and/or membrane. Staining intensity was not
evaluated.
Statistical analysis
Selection of cut-off scores for protein positivity Relevant cut-off
scores for tumour positivity for each protein marker were obtained
by performing receiver-operating characteristic (ROC) curve
analysis (Zlobec et al, 2006b). Briefly, plots of sensitivity and
(1-specificity) for complete pathologic tumour response were
obtained for each marker and the (0,1)-criterion was used to select
the threshold value, or protein expression score, above which
expression was to be considered ‘positive’ (Bewick et al, 2004). In
order to determine the reliability of the ROC curve-derived cut-off
score, resampling of the data using 100 bootstrapped replications
was performed for all proteins. To determine the discriminatory
power of each marker for complete pathologic response, the area
under the ROC curve (AUC), standard error (s.e.) and 95% CI were
obtained for each. The closer the AUC to 1.0 is, the greater the
predictive power of the marker for complete tumour response.
Association with clinicopathological features at the
respective cut-offs
The association of complete tumour response with both clinico-
pathological features and protein expression was analysed using
logistic regression and where appropriate, with Fisher’s Exact test.
The P-values, odds ratio (OR) and 95% CI for each analysis were
obtained. A Bonferroni correction for multiple comparisons was
performed. To maintain an overall type I error rate of 0.05, each
test of association with complete pathologic response was
considered significant if Po0.005. All variables significant in
univariate analysis were entered into a multiple logistic regression
model. Statistical interactions between significant variables were
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Institute, Cary, NC, USA).
RESULTS
Clinicopathological features
Patient characteristics are summarised in Table 1. Thirty-three
(31.7%) patients had a complete pathologic tumour response to
preoperative HDREB. Seventy-one (68.3%) were found to have
residual carcinoma, including 35 patients (34.3%) who were
considered as partial responders due to the presence of microfoci
of residual carcinoma. Ninety-six (94.1%) patients were preopera-
tively staged as cT3. pT stage was available for 80 patients, of
which 31 (38.8%) were pT0, 12 (15.0%) were downstaged to pT1,
17 (21.3%) were pT2 and 20 cases (25.0%) were pT3.
Selection of cut-off scores based on ROC curve analysis
Cut-off scores were determined to be 50% for p53, 20% for VEGF,
Bcl-2 and EGFR and 10% for APAF-1. Tumours with scores above
the obtained cut-off values were considered positive for the
expression of the protein. The corresponding AUCs (95% CI)
are listed in Table 2. AUCs were the largest for EGFR (0.66
(0.54–0.78)) and VEGF (0.64 (0.51–0.77) indicating that the
discriminatory power for complete response was the greatest for
these two markers.
Univariate analysis
The association of protein expression with complete pathologic
response (Table 2) demonstrated that negative VEGF expression
(P-value¼0.004, OR (95% CI)¼0.23 (0.09–0.63)) and EGFR
positivity (P-value¼0.003, OR (95% CI)¼5.78 (1.85–18.07)) were
significantly associated with complete tumour response after
correction for multiple comparisons while p53, APAF-1 and
Bcl-2 demonstrated no predictive ability for the outcome. Loss of
VEGF expression was associated with more than a 4.3 times greater
chance of complete tumour response compared with VEGF-
positive tumours, while EGFR positivity resulted in a 5.78 times
increased odds of complete tumour regression. Representative
immunostains of VEGF and EGFR are illustrated in Figure 1.
Multivariable analysis
VEGF and EGFR were entered into multivariable analysis. Eighty-
eight tumours could be evaluated, of which 27 (31%) had a
complete pathologic response. Loss of VEGF (P-value¼0.009; OR
(95% CI)¼0.24 (0.08–0.69)) and positive EGFR (P-value¼0.01;
OR (95% CI)¼3.82 (1.37–10.6)) both demonstrated independent
Table 1 Clinicopathological characteristics of rectal cancer patients
treated with high-dose-rate brachytherapy
Total
Frequency
Clinicopathological feature nn (%)
Sex
Female 104 74 67.3
Male 36 32.7
Tumour grade (differentiation)
Well 92 21 22.8
Moderate 67 72.8
Poor 4 4.4
Tumour response
Complete 104 33 31.7
Partial 35 33.6
None 36 34.6
cT stage
cT1 102 0 0
cT2 2 2.0
cT3 96 94.1
cT4 4 3.9
PT stage
pT0 80 31 38.8
pT1 12 15.0
pT2 17 21.2
pT3 20 25.0
Table 2 ROC curve-derived cut-off scores, area under the curve (AUC) and association of protein expression with complete pathologic response
Cut-off score AUC (95% CI) Total (n) No complete response, n (%) Complete response, n (%) P-value OR (95% CI)
p53
p50% 0.529 (0.39–0.66) 92 41 (70.7) 17 (29.3) 0.359 1.55 (0.61–3.96)
450% 22 (64.7) 12 (35.3)
VEGF
p20% 0.64 (0.51–0.77) 89 12 (48.0) 13 (52.0) 0.004 0.23 (0.09–0.63)
420% 49 (76.6) 15 (23.4)
Bcl-2
p20% 0.546 (0.41–0.68) 90 49 (72.1) 19 (27.9) 0.203 2.02 (0.68–5.99)
420% 13 (59.1) 9 (40.9)
APAF-1
p10% 0.538 (0.41–0.67) 88 40 (71.4) 16 (28.6) 0.137 2.07 (0.8–5.38)
410% 20 (62.5) 12 (37.5)
EGFR
p20% 0.66 (0.54–0.78) 90 40 (80.0) 10 (20.0) 0.003 5.78 (1.85–18.07)
420% 22 (55.0) 18 (45.0)
APAF-1¼apoptosis protease-activating factor-1; CI¼confidence interval; EGFR¼epidermal growth factor receptor; OR¼odds ratio; ROC¼receiver-operating characteristic;
VEGF¼vascular endothelial growth factor.
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spredictive value for complete pathologic response. Multi-marker
combinations of VEGF and EGFR were analysed and summarised
in Table 3. Positive VEGF and negative EGFR expression were
significantly associated with lack of complete pathologic response
(Po0.001) compared with all other multi-marker combinations.
The odds of complete response were 12.8 for VEGF-negative and
EGFR-positive tumours compared with VEGF-positive and EGFR-
negative tumours. Moreover, of the 34 EGFR-negative cases, which
simultaneously had VEGF positivity, 32 (94.1%) had no complete
pathologic response. These results are highlighted in Figure 2.
DISCUSSION
The aim of this study was to determine whether pretreatment
expression levels of five immunohistochemical markers including
p53, Bcl-2, APAF-1, VEGF and EGFR could predict complete
pathologic tumour regression in patients with advanced rectal
cancer undergoing preoperative radiotherapy. Our findings
indicate that VEGF and EGFR are independent predictive factors
and their combined analysis is highly predictive of complete
pathologic response.
Prognostic or predictive studies evaluating immunohisto-
chemical markers, including EGFR, have often yielded irreproducible
results. Several sources of discrepancy have been recognised as
contributing to the conflicting reports in the literature between
similar studies, including methodological differences such as
various fixation protocols and antibodies (Atkins et al, 2004;
McShane et al, 2005). The interpretation of immunoreactivity is
underlined as a major source of contradictory findings (Goldstein
and Armin, 2001; Resnick et al, 2004; Spano et al, 2005; Kim et al,
2006; Li et al, 2006). In order to avoid the use of predetermined
and often arbitrarily set cut-off values, we have previously shown
how ROC curve analysis in conjunction with a resampling
procedure can be systematically used to evaluate the protein
expression of immunohistochemical tumour markers (Zlobec
et al, 2007a). Along with a reproducible semi-quantitative scoring
system, ROC curve analysis is a powerful method for selecting cut-
off scores to describe tumour marker positivity for a specific
clinical endpoint, such as tumour response. In addition, we have
recently demonstrated that assessment of staining intensity
between independent observers results in low to moderate inter-
observer agreement whereas the semi-quantitative evaluation of
protein expression is highly reproducible between multiple
observers and sufficient for providing the necessary information
on the associations of protein markers with different clinicopatho-
logical endpoints (Zlobec et al, 2006a, 2007b,c).
By applying ROC curve derived cut-off scores to the immuno-
histochemical markers in this study, we found that VEGF negative
tumours were more than four times more likely to undergo a
complete tumour regression than their VEGF positive counter-
parts. Complete pathologic response was nearly six times more
likely in EGFR-positive tumours compared with EGFR-negative
cases. Moreover, analysis of multi-marker phenotypes of VEGF
and EGFR expression identified a subgroup of VEGF-positive and
EGFR-negative tumours that were highly resistant to treatment.
VEGF is a potent angiogenic promoter required for the full
execution of angiogenesis. VEGF receptor signalling has been
shown to have effects on endothelial cell proliferation, migration,
survival and vascular permeability (Roskoski, 2007). In addition,
urokinase plasminogen activator, tissue plasminogen activator and
matrix metalloproteinases are induced by upregulation of VEGF.
These proteins function to degrade the basement membrane
and extracellular matrix, providing a scaffold for proliferating,
migrating and extravasating endothelial cells (Ferrara et al, 2003).
The result of tumour angiogenesis is a newly formed vasculature
with ‘leaky’, disorganised vessels, increased interstitial pressure and
chaotic blood flow, which decreases the efficiency of radiotherapy
(Willett et al, 2006; Roskoski, 2007). In 1971, Folkman (1971)
hypothesised that blocking angiogenesis in tumours could be
used a method of treatment for patients with cancer. Pharmaco-
logical agents designed to block VEGF or VEGF receptor signalling
are currently in various phases of clinical trials and have
demonstrating promising results (Kowanetz and Ferrara, 2006;
Roskoski, 2007; Willett et al, 2007). The VEGF blockade results in
AB
Figure 1 Representative immunostains of VEGF (A) and EGFR (B) from pretreatment rectal tumour biopsies.
Table 3 Multi-marker phenotype combinations of VEGF and EGFR in
patients undergoing preoperative HDREB
VEGF EGFR Total (n)
No complete
response
Complete
response
Negative Negative 15 7 (46.7) 8 (53.3)
Negative Positive 9 5 (55.6) 4 (44.4)
Positive Negative 34 32 (94.1) 2 (5.9)
Positive Positive 30 17 (56.7) 13 (43.3)
Total 88 61 27
EGFR¼epidermal growth factor receptor; HDREB¼high-dose-rate endorectal
brachytherapy; VEGF¼vascular endothelial growth factor.
Negative
Negative Negative
Positive
Positive
(7, 8)
(46.7%, 53.3%)
(32, 2)
(94.1%, 5.9%)
(5, 4)
(55.6%, 44.4%)
(17, 13)
(56.7%, 43.3%)
Positive
EGFR
VEGF VEGF
Figure 2 Decision tree summarising the frequency of complete tumour
response with various multi-marker phenotype combinations. In first
parentheses under each decision arm: number of patients with no
complete response, number of patients with complete response. In second
parentheses: proportion of patients with no complete response, proportion
of patients with complete response.
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s‘normalisation’ of the vasculature, decreased interstitial pressure
and vascular permeability, thereby potentiating the effects of
radiotherapy by increasing oxygen transport to tumour cells and
facilitating the delivery of chemotherapeutic agents to the target
tumour (Willett et al, 2006). In our study, VEGF positivity was
strongly associated with a more radio-resistant phenotype.
In colorectal cancer, VEGF is associated with tumour aggres-
siveness, poor survival, local failure and the presence of metastatic
disease (Giatromanolaki et al, 2006). Giralt et al (2007) demon-
strated that VEGF positivity is an indicator of poor disease-free
survival following preoperative radiochemotherapy, while Nozue
et al (2001) described an association between post-treatment VEGF
overexpression and distant metastasis. Qiu et al (2000) found no
correlation between pretreatment VEGF expression and tumour
response in 72 patients undergoing long-course neoadjuvant
radiotherapy. In a previous work on the same, yet smaller series
of patients, we not only identified VEGF but also Bcl-2 as
significant predictors of tumour regression (Zlobec et al, 2005).
Bcl-2-negative tumours experienced a partial or complete tumour
regression more often than Bcl-2-positive cases. This protein,
however, was not associated with complete tumour regression in
this study, a discrepancy that is likely due to the different clinical
endpoints evaluated in our previous and current works. These
results suggest a possible role for Bcl-2 in tumour regression,
which requires further elucidation. To our knowledge, the present
study is the first to have evaluated complete pathologic response
and pretreatment VEGF expression in rectal tumours. Our results
clearly demonstrate that patients with VEGF-negative tumours
before treatment should be considered candidates for preoperative
radiotherapy.
Although the prognostic role of EGFR has been frequently
investigated, only few studies have assessed the predictive value of
pretreatment EGFR expression in preoperative radio- or radio-
chemotherapy. Recent reports are conflicting. While Giralt et al
(2005) found a significant association between EGFR overexpres-
sion and a lack of complete pathologic tumour regression to
preoperative radiotherapy, Bertolini et al (2007) reported no such
result. The findings of our study indicate that pretreatment EGFR
expression is an indicator of complete pathologic response and
strongly supports the treatment of these patients with preoperative
radiotherapy. Recently Jonker and co-workers assessed the value
of the anti-EGFR therapy cetuximab on a large cohort of 572
patients with advanced EGFR-expressing colorectal cancers who
failed to respond to previous chemotherapy, and found a
significant improvement in overall survival in these patients.
Anti-EGFR therapy may further improve clinical outcome in our
series our EGFR-positive, and more radiosensitive patients treated
with HDREB (Jonker et al, 2007).
Although our results, which indicate improved outcome in
patients with positive EGFR, appear to conflict with the majority of
reports in colorectal cancer, our findings are in line with previous
studies in head and neck squamous cell carcinoma (HNSCC)
using moderately accelerated or hyperfractionated accelerated
radiotherapy. Eriksen et al (2005) investigated 803 patients
randomised to 5 vs 6 fractions per week of radiotherapy. They
found that high-EGFR tumours responded better to moderately
accelerated radiotherapy compared with EGFR-low tumours, and
determined that response to accelerated fractionation may be
predicted by high EGFR expression in pretreatment tissue samples.
Bentzen and co-workers performed IHC on 304 patients rando-
mised to receive CHART vs conventionally fractionated radio-
therapy. They concluded that there was a significant benefit from
strongly accelerated CHART in patients with high EGFR expres-
sion and no benefit in patients with a low EGFR index (Bentzen
et al, 2005). These results suggest that the predictive value of EGFR
to radiotherapy may be dependent on the dose fractionation
regimen.
In our combined analysis of VEGF and EGFR expression, both
markers had independent value for predicting a complete
pathologic tumour regression. Simultaneous VEGF-positive and
EGFR-negative expression was associated with a lack of complete
tumour regression in more than 94% of cases and a 12-fold-
decreased odds of response compared with EGFR-positive and
VEGF-negative tumours. A relationship between EGFR and VEGF
has previously been established. Not only do both proteins share
the same intracellular signalling pathways (Roberts and Der, 2007),
but several preclinical studies have provided evidence for either
direct or indirect angiogenic effects of EGFR signalling (Ciardiello
et al, 2006). EGFR has additionally been reported to upregulate
VEGF expression (Ciardiello et al, 2006). Recently Eriksen et al
(2005) demonstrated that EGFR tyrosine kinase inhibitors decrease
VEGF expression by both HIF-1a-independent and -dependent
mechanisms. Although interrelated, the contribution of VEGF and
EGFR to angiogenesis appears to arise through distinct mecha-
nisms, thereby warranting the simultaneous blockade of both
proteins for the treatment of patients with rectal cancer
(Tabernero, 2007).
We acknowledge that preoperative HDREB remains an experi-
mental approach that is presently being considered for a
randomised trial. At the present time, different radiation schedules
are used: in northern Europe, 25Gy in five fractions (short course)
is commonly applied, whereas 45Gy in 25 fractions (long course)
with chemotherapy is preferred in southern Europe and North
America. Bujko et al (2006) randomised 310 patients with cT3
rectal cancer to 5Gy  5, followed by surgery or conventional
preoperative 50.4Gy plus bolus 5FU1leucovorin daily over 5
weeks, followed by surgery and reported similar local control and
survival results. The ability to predict complete pathologic
response or sensitivity to radiation based on IHC would have a
significant impact on the selection of patients for preoperative
radiotherapy or chemoradiation therapy schedules.
In this study, negative VEGF and positive EGFR expression were
predictive of complete pathologic response to preoperative radio-
therapy in patients with advanced rectal cancer. In addition, our
findings have identified a subgroup of VEGF-positive and EGFR-
negative tumours, which are more resistant to radiotherapy and
should perhaps be considered candidates for innovative neoadju-
vant combined modalities.
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